Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2023-05-04 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT – Q1 2023' and contains comprehensive financial statements, including a consolidated statement of comprehensive income, statement of financial position, and detailed management commentary on business performance, cash flow, and risks. It covers a period shorter than a full fiscal year (January-March 2023). It is not an announcement of a report, but the report itself, containing substantive financial data. Q1 2023
2023-05-04 English
Oncopeptides issues warrants to utilize the first loan tranche from EIB
Capital/Financing Update Classification · 1% confidence The document announces that Oncopeptides has decided to utilize the first tranche of a loan agreement with the European Investment Bank (EIB) and, consequently, resolved on an issue of warrants to the EIB as part of the loan terms. This action involves securing financing (€10 million tranche) and issuing securities (warrants) related to that financing. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is moderate, and it is a direct announcement of the financing event, not just a notice that a report is attached.
2023-05-03 English
Oncopeptides utfärdar teckningsoptioner för att nyttja första lånetranchen från EIB
Capital/Financing Update Classification · 1% confidence The document announces that Oncopeptides AB has decided to utilize the first tranche of a loan agreement with the European Investment Bank (EIB) and simultaneously decided on the issuance of warrants (teckningsoptioner) to EIB as part of the loan terms. This action directly relates to the company's financing activities and capital structure changes (issuing warrants linked to a loan). This fits the definition of 'Capital/Financing Update' (CAP). Although it involves warrants (which could sometimes relate to SHA), the primary driver and context is the utilization of the EIB loan tranche, making CAP the most appropriate classification.
2023-05-03 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 1% confidence FY 2022
2023-04-25 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 1% confidence FY 2022
2023-04-25 Swedish
Årsstämma i Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is titled "Årsstämma i Oncopeptides AB (publ)" which translates to "Annual General Meeting in Oncopeptides AB (publ)". The text details the date, time, location, registration procedures, voting methods (in person or advance voting), and the proposed agenda for the meeting. The agenda items explicitly cover the election of the board, auditors, approval of remuneration reports, and proposals for long-term shareholder programs, which are standard topics for an AGM. This clearly identifies the document as material related to the Annual General Meeting.
2023-04-21 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.